Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-hydroxycoumarin is a small molecule and a hydroxy derivative of coumarin. It serves as the core scaffold for a class of anticoagulant drugs known as the 4-hydroxycoumarins (including warfarin and dicoumarol), which act as vitamin K antagonists by inhibiting vitamin K epoxide reductase. While derivatives with large aromatic substituents at the 3-position are potent anticoagulants used clinically to prevent and treat thromboembolic disorders, **the parent compound itself (4-hydroxycoumarin) is not an active anticoagulant** but is widely used in pharmaceutical research and synthesis. It also exhibits antioxidant properties and has been studied for potential antibacterial, antifungal, antiviral, anti-inflammatory, antitumor activities and as an inhibitor of HIV-1 integrase[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-hydroxycoumarin.